{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"A Phase 3, Randomized, Open-Label, Multicenter Study to 'Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma&#160;(QUINTESSENTIAL-2)","eudractNumber":"2022-501346-30-00","id":9854,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06615479","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-01T09:47:06+02:00","shortTitle":"BMS CA088-1007","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants with Relapsed and/ or Refractory Multiple Myeloma; Studienteil: Expansionsphase","eudractNumber":"2023-506003-26-00","id":9082,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06153251","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2025-01-16T09:48:50+01:00","shortTitle":"BMS CA119-0002","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus</div><div>Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with</div><div>Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung</div><div>Cancer with KRAS G12C Mutation (KRYSTAL-4)</div>","eudractNumber":"2024-515698-85-00","id":11377,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"KRAS","id":"mt_7"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS-G12C","id":"mt_250"},{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06875310","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-30T08:29:20+02:00","shortTitle":"BMS CA239-0004 (KRYSTAL-4)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of \nBMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung \nCancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies","eudractNumber":"2024-519814-29","id":10710,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"ALK","id":"mt_11"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF","id":"mt_9"},{"name":"EGFR","id":"mt_1"},{"name":"HER2/neu","id":"mt_19"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"NTRK","id":"mt_81"},{"name":"RET (Rezeptor-Tyrosinkinase)","id":"mt_76"},{"name":"ROS-1 (c-ros oncogene 1, receptor tyrosine kinase)","id":"mt_12"}],"nctNumber":"NCT06855771","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-12T13:09:19+02:00","shortTitle":"BMS-CA240-0009","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"Epidemiologische Studie zur Bestimmung der Pr&#228;valenz von ctDNA-Positivit&#228;t bei Teilnehmern mit CRC im Stadium II (hohes Risiko) oder Stadium III nach einer Operation mit kurativer (R0) Absicht und anschlie&#223;ender adjuvanter Chemotherapie mit &#220;berwachung der ctDNA w&#228;hrend der klinischen Nachsorge","eudractNumber":null,"id":8552,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT04813627","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-04-20T08:23:42+02:00","shortTitle":"BNT000-001","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p style=\"margin:0in;\">An open label Phase\nII randomized trial of BNT113 in\ncombination with pembrolizumab versus\npembrolizumab monotherapy as a first line therapy in patients with\nunresectable recurrent, or metastatic Head and Neck Squamous Cell\nCarcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+)\nand expresses PD-L1&#160;(AHEAD-MERIT)</p>","eudractNumber":"2020-001400-41","id":6731,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[{"name":"HPV16","id":"mt_86"},{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT04534205","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-04-11T15:21:31+02:00","shortTitle":"BNT113-01 (AHEAD-MERIT)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"RNA Disruption Assay (RDA) <b>Br</b>east cancer <b>R</b>esponse <b>EV</b>aluation for<b> I</b>ndividualized <b>T</b>herap<b>Y</b>-02 (BREVITY-02)","eudractNumber":null,"id":7611,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT03524430","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-03-26T09:18:26+01:00","shortTitle":"BREVITY-02","therapeutical":false,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"<div>PiR-HoP aimed at establishing a multi-site prospective clinical registry for two specific groups of prostate cancer patients, who present a particular clinical challenge:</div><div>&#61623; the oligometastatic prostate cancer</div><div>&#61623; the high risk prostate cancer in young patients</div>","eudractNumber":null,"id":11017,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-08-02T08:53:09+02:00","shortTitle":"BZKF- PiR-hoP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive Erfassung von klinischen Daten, Bildgebungsdaten, Strahlentherapie-Planungsdaten und Biomaterialien zur integrierten Analyse von Therapieansprechen und -resistenz sowie Aufdeckung molekularer Zielstrukturen bei Adoleszenten und jungen Erwachsenen mit ZNS-Tumoren","eudractNumber":null,"id":10994,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT06323408","phase":null,"recruitmentStart":"2024-09-23T15:22:25+02:00","shortTitle":"BZKF-AYA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"PARP-Inhibitor Reinduktion beim rezidivierenden Ovarialkarzinom: Versorgungsrealit&#228;t in \nBayern, translationale Biomarker und klinische Ergebnisse","eudractNumber":null,"id":9729,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-10-14T10:33:31+02:00","shortTitle":"BZKF-OVAR-1","therapeutical":false,"therapyLines":[]}]}